Contributed by Joshua D. Grill, PhD, Director of UCI MIND Early Monday morning (February 10, 2020), the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) and Eli Lilly & Company announced disappointing results from a clinical trial of the monoclonal antibody, solanezumab, against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease (press release >). The DIAN includes only the rare families who carry genetic mutations that cause an early-onset (3rd, 4th, 5th decade of life) form of Alzheimer’s disease. Solanezumab is also being tested as part of the Anti-Amyloid treatment in Asymptomatic Alzheimer’s (A4) Study, which is ongoing…
Read More
ASK THE DOC! UCI MIND Facebook LIVE Video Series This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Are you getting enough sleep for your brain? About the Speaker: Dr. Ruth Benca is a Professor and Chair of Psychiatry & Human Behavior in the UCI School of Medicine and Founding Director…
Read More
Faculty members Mathew Blurton-Jones, PhD, Kim Green, PhD, and Masashi Kitazawa, PhD, are principal investigators (PI) of productive, independent laboratories at UCI MIND all aiming to target the underlying cause of and develop effective treatments for Alzheimer’s disease (AD) and related disorders. How did they get to where they are now? After graduate school in 2003, they came together from different backgrounds to train with renowned scientist, Frank LaFerla, PhD, who continues to run a successful laboratory of his own at UCI MIND. Blurton-Jones, Green, and Kitazawa reflect on their training experience and what they believe to be their…
Read More
It is with great sadness that UCI MIND shares news about the passing of Dr. Frieda Rapoport Caplan, founder of Frieda’s Specialty Produce and a tremendous supporter of brain research. Frieda was 96 years of age when she passed on Saturday. She was a pioneer in many powerful ways. A leader in the U.S. wholesale produce business since 1962, Frieda was the first woman to own and run her own firm. Her specialty was introducing unusual produce to the U.S. market, bringing more than 200 fruits and vegetables from around the world to America. She marketed each new product with…
Read More
Jan 14, 2020 Announcements and research updates from the The Women's Alzheimer's Movement - WAM and UCI MIND Initiative to fund sex disparities in #Alzheimers research at University of California, Irvine. Congratulations to Mathew Blurton-Jones, PhD and Sunil Gandhi, PhD from the UCI School of Biological Sciences and Anshu Agrawal, PhD from the UCI School of Medicine, recipients of seed funding grants made possible by WAM Founder Maria Shriver and the Living Legacy Foundation led by VP and Executive Director Alisha Ballard.
Read More
ASK THE DOC! UCI MIND Facebook LIVE Video Series This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. When will we have an effective treatment for Alzheimer's disease? About the Speaker: Joshua Grill, PhD, is an Associate Professor of Psychiatry & Human Behavior and Neurobiology & Behavior at UCI. He serves…
Read More
